Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis

Company Overview

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.

Key Stats

• Today's Range: €41.60 to €42.00
• 50-Day Range: €41.20 to €42.40
• 52-Week Range: €40.40 to €43.40
• Volume: 1 shs
• Average Volume: 1,927 shs
• Market Capitalization: $823.26 million
• P/E Ratio: 10.02
• Dividend Yield: 0.10%
• Price Target: N/A
• Consensus Rating: N/A

BIO Stock Analysis - Frequently Asked Questions

How have BIO shares performed this year?

Biotest Aktiengesellschaft's stock was trading at €42.60 on January 1st, 2024. Since then, BIO shares have decreased by 2.3% and is now trading at €41.60.
View the best growth stocks for 2024 here.

What other stocks do shareholders of Biotest Aktiengesellschaft own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biotest Aktiengesellschaft investors own include GSK (GSK), Invitae (NVTA), Adaptive Biotechnologies (ADPT), ADMA Biologics (ADMA), Analog Devices (ADI), Adaptimmune Therapeutics (ADAP) and Axcelis Technologies (ACLS).

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: ETR:BIO
• CUSIP: N/A
• CIK: N/A
• Web: www.biotest.com
• Phone: +49-6103-8010
• Fax: N/A
• Employees: 8,200
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): €4.15
• Trailing P/E Ratio: 10.02
• Forward P/E Ratio: 346.67
• P/E Growth: N/A
• Net Income: $164.40 million
• Net Margins: 21.04%
• Pretax Margin: N/A
• Return on Equity: 36.16%
• Return on Assets: 8.47%

Debt

• Debt-to-Equity Ratio: 116.50
• Current Ratio: 2.45
• Quick Ratio: 1.66

Sales & Book Value

• Annual Sales: $781.30 million
• Price / Sales: 1.05
• Cash Flow: €1.34 per share
• Price / Cash Flow: 31.04
• Book Value: €13.26 per share
• Price / Book: 3.14

Miscellaneous

• Outstanding Shares: 19,790,000
• Free Float: N/A
• Market Cap: $823.26 million
• Optionable: Not Optionable
• Beta: 0.24